Stay updated on Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page.

Latest updates to the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page
- CheckyesterdayChange DetectedAdded a new Locations section listing Tennessee (Nashville, Vanderbilt-Ingram Cancer Center) as a study site. Removed the separate Tennessee Locations entry in the footer.SummaryDifference0.2%

- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check29 days agoChange DetectedThe page now shows Revision: v3.3.2 instead of v3.2.0, with no changes to the study details.SummaryDifference0.1%

- Check36 days agoChange DetectedRemoved the site-wide funding-status notice about potential delays in updates and operating-status information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check51 days agoChange DetectedThe new screenshot shows the same study details page with only cosmetic differences (layout spacing and minor text formatting) and no evident changes to the core study content such as eligibility criteria, interventions, endpoints, or enrollment. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check79 days agoChange DetectedSignificant update: new operating-status notice and v3.2.0 version released, replacing v3.1.0.SummaryDifference3%

- Check86 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; no other substantive content changes detected.SummaryDifference0.1%

Stay in the know with updates to Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Relatlimab in Metastatic Melanoma Clinical Trial page.